EHA 2017: The Nature of Long Remissions
“I still haven’t found what I’m looking for.” U2 What makes one patient’s remission longer than another? Dr.Bruno Paiva of…
Cost of Care: ASH Applauds Access to Treatment Bill
This Press Release was originally published by ASH. ASH President Applauds Introduction of Patients’ Access to Treatment Act (WASHINGTON, June 23, 2017)…
Full Show: New Bi-Specific Antibody Hitting Two Targets in Myeloma, Dirk Hose, MD and Anja Seckinger, MD, University of Heidelberg
Dirk Hose, MD Anja Seckinger, MD Interview Date: May 24, 2017 Summary Many myeloma patients are familiar with monoclonal antibodies,…
Full Show: New Bi-Specific Antibody Hitting Two Targets in Myeloma, Dirk Hose, MD and Anja Seckinger, MD, University of Heidelberg
Dirk Hose, MD Anja Seckinger, MD Interview Date: May 24, 2017 Summary Many myeloma patients are familiar with monoclonal antibodies,…
Our Next Show: Targeting BCMA and T Cells in New Bi-Specific Myeloma Antibody with Anja Seckinger, MD and Dirk Hose, MD, University of Heidelberg, Wednesday, May 24 @ 10 am Central
Wednesday, May 24, 2017 @ 8 am Pacific, 9 am Mountain, 10 am Central, 11 am Eastern Call In by…
Clinical Trial: More Options for Patients Refractory to Lenalidomide
Over the course of their care, patients may become refractory to one of the mainstay drugs, lenalidomide. Lenalidomide is of…
UPCOMING MYELOMA CROWD ROUNDTABLES
August 19, 2017, Myeloma Crowd Round Tables: Jackson, Mississippi
Myeloma Crowd Round Tables are day-long meetings that provide patients and caregivers updated information so…
September 23, 2017, Myeloma Crowd Round Tables: Detroit, Michigan
Myeloma Crowd Round Tables are day-long meetings that provide patients and caregivers updated information so…
MYELOMA CROWD RESEARCH CAMPAIGNS
Myeloma Crowd Research Initiative (MCRI) Funds Two Immunotherapy Projects
The Myeloma Crowd Initiative selected two proposals it has selected for the MCRI crowdsourcing and…
Continuing the Fight for a Myeloma Cure: Dr. Tricot and Dr. Zhan’s Research to Improve Outcomes for High-Risk Myeloma Patients
Guido Tricot, MD, PhD has devotedly attended to thousands of multiple myeloma patients for over…
Thanks to our site sponsors:
